Kaburaki Kyohei, Isobe Kazutoshi, Kobayashi Hiroshi, Yoshizawa Takahiro, Takai Yujiro, Homma Sakae
Division of Respiratory Medicine, Omori Medical Center, Toho University School of Medicine, Tokyo 143-8541, Japan.
Mol Clin Oncol. 2017 Apr;6(4):510-514. doi: 10.3892/mco.2017.1187. Epub 2017 Mar 8.
The aim of this prospective study was to evaluate the efficacy and feasibility of bevacizumab combined with vinorelbine therapy in patients with previously treated non-squamous non-small-cell lung cancer (nonSq-NSCLC). Patients who had received at least one prior chemotherapy course were eligible for this study. The patients were treated with vinorelbine (25 mg/kg on days 1 and 8) and bevacizumab (15 mg/kg on day 1), which was repeated every 3 weeks until the development of progressive disease or unacceptable toxicity. Between June, 2011 and January, 2013, 15 patients were enrolled. The response and disease control rates were 26.7 and 73.3%, respectively. The median progression-free survival was 2.1 months and the median overall survival was 34.1 months. Grade 3-4 phlebitis occurred in 3 patients. Therefore, the combination of vinorelbine and bevacizumab was found to be effective in patients with previously treated nonSq-NSCLC, but physicians must be aware of the risk of phlebitis associated with this regimen.
这项前瞻性研究的目的是评估贝伐单抗联合长春瑞滨治疗既往接受过治疗的非鳞状非小细胞肺癌（nonSq-NSCLC）患者的疗效和可行性。接受过至少一个疗程先前化疗的患者符合本研究条件。患者接受长春瑞滨（第1天和第8天25mg/kg）和贝伐单抗（第1天15mg/kg）治疗，每3周重复一次，直至出现疾病进展或不可接受的毒性。2011年6月至2013年1月，共纳入15例患者。缓解率和疾病控制率分别为26.7%和73.3%。中位无进展生存期为2.1个月，中位总生存期为34.1个月。有3例患者发生3-4级静脉炎。因此，发现长春瑞滨和贝伐单抗联合治疗对既往接受过治疗的nonSq-NSCLC患者有效，但医生必须意识到该治疗方案相关的静脉炎风险。
